Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-301 tarlatamab in relapsed/refractory small cell lung cancer
NL-OMON54228Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Jun 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tarlatamab in small cell lung cancer (SCLC) (4 arms), sponsored by Amgen. Primary endpoints: Objective response, Objective response by blinded independent central review and 2 more. Started Jun 2022; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON54228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54228.